Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan.
Bioorg Med Chem. 2011 Nov 1;19(21):6430-46. doi: 10.1016/j.bmc.2011.08.070. Epub 2011 Sep 5.
We synthesized a series of novel 3-phenyl-4-benzylaminopiperidine derivatives that were identified as potent tachykinin NK(1) receptor antagonists by structural modification of the 3-benzhydrylpiperidone derivative through high-throughput screening. N-{2-[(3R,4S)-4-({2-Methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl}amino)-3-phenyl-1-piperidinyl]-2-oxoethyl}acetamide ((+)-39) was found to be one of the most potent tachykinin NK(1) receptor antagonists with high metabolic stability. Highly efficient asymmetric synthesis of (+)-39 was achieved via dynamic kinetic resolution.
我们通过高通量筛选对 3-苯甲酰基哌啶酮衍生物进行结构修饰,合成了一系列新型 3-苯基-4-苄基氨基哌啶衍生物,这些衍生物被鉴定为强效速激肽 NK(1)受体拮抗剂。N-{2-[(3R,4S)-4-{2-甲氧基-5-[5-(三氟甲基)-1H-四唑-1-基]苄基}氨基)-3-苯基-1-哌啶基}-2-氧代乙基}乙酰胺((+)-39)被发现是最有效的速激肽 NK(1)受体拮抗剂之一,具有较高的代谢稳定性。通过动态动力学拆分,高效地完成了(+)-39 的不对称合成。